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Use of the Xpert MTB/RIF assay in the 
diagnosis of tuberculous meningitis:  
A cautionary note
To the Editor: The Xpert MTB/RIF (Cepheid) assay is a nucleic 
acid amplification test developed to detect mycobacterial tuberc­
ulosis (MTB) infection and rifampicin resistance. It is a closed 
system, requires minimal training to use, and produces a result in a 
few hours. When used as an initial diagnostic test replacing smear 
microscopy for pulmonary tuberculosis, the Xpert MTB/RIF has 
a pooled sensitivity of 88%.[1] The application of this test has been 
extended to extrapulmonary samples, including cerebrospinal fluid 
(CSF).
The World Health Organization (WHO) evaluated the results 
of 709 CSF samples tested with Xpert MTB/RIF in 16 studies 
using culture as a reference standard. Sensitivity varied widely, 
ranging from 51% to 100%.[1] Using a 3 ml volume of CSF and 
including a concentration step increased sensitivity.[1,2] The WHO 
recommends that the Xpert MTB/RIF should be the first test to 
be undertaken on CSF from patients with suspected tuberculous 
meningitis (TBM). However, caution is advised, as the following 
case illustrates.
A 43­year­old HIV­positive man was admitted to a peripheral 
hospital in South Africa with a 2­week history of headache and a 
more recent onset of slurred speech, inability to walk and impaired 
consciousness. A computed tomography scan of the brain showed 
mild hydrocephalus and basal enhancement. Lumbar puncture 
revealed an opening pressure of 4 cm H2O, yellow colour, lympho­
cytes 300/l, a protein level of 1.06 g/l and glucose level of 1.3 
mmol/l. The Xpert MTB/RIF was negative. On the basis of this 
negative test result, initiation of antituberculosis (anti­TB) therapy 
was deferred and ceftriaxone was started. The patient was referred 
to the neurology unit at Inkosi Albert Luthuli Central Hospital in 
Durban 4 days later. He was noted to have a Glagow Coma Score 
of 8/15, meningism and normal optic fundi. He could move all his 
limbs. Anti­TB drugs and steroids were commenced, but he died 
within 3 hours of admission.
Ignoring the Xpert MTB/RIF result, this patient’s clinical, 
radiological and CSF profile is consistent with probable TBM.
[3] As standard of care, he would have been started on anti­TB 
therapy and steroids while awaiting the other laboratory results. 
The WHO, understandably, based its recommendation on studies 
done in research settings, where as much as 3 ml of CSF was used 
in at least one study.[2] For busy routine laboratories the extra step of 
concentration may be burdensome, and moreover they are unlikely 
to receive such a large volume of CSF.
As this test for TBM becomes more widely available it will 
be requested at all levels of care by medical personnel who have 
varying degrees of clinical skill, knowledge and experience. Herein 
lies the concern. Clinicians need to understand that, as with other 
tests for diagnosis of TBM, the Xpert MTB/RIF is a good ‘rule­in’ 
test (i.e. specificity approaching 100%) but a poor ‘rule­out’ test 
(moderate sensitivity).[4] A negative test does not exclude TBM. 
Clinical judgement is required. Any delay in initiating therapy risks 
an unacceptable outcome for the patient. 
The Xpert MTB/RIF test should be subjected to post­WHO 
recommendation scrutiny to determine how well it performs in 
routine clinical practice for the diagnosis of TBM.
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